Cargando…
In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index
In vitro-based search for promising anti-cancer drug combinations may provide important leads to improved cancer therapies. Currently there are no integrated computational-experimental methods specifically designed to search for combinations, maximizing a predefined therapeutic index (TI) defined in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585751/ https://www.ncbi.nlm.nih.gov/pubmed/26392291 http://dx.doi.org/10.1038/srep14118 |
_version_ | 1782392268331679744 |
---|---|
author | Kashif, M. Andersson, C. Hassan, S. Karlsson, H. Senkowski, W. Fryknäs, M. Nygren, P. Larsson, R. Gustafsson, M.G. |
author_facet | Kashif, M. Andersson, C. Hassan, S. Karlsson, H. Senkowski, W. Fryknäs, M. Nygren, P. Larsson, R. Gustafsson, M.G. |
author_sort | Kashif, M. |
collection | PubMed |
description | In vitro-based search for promising anti-cancer drug combinations may provide important leads to improved cancer therapies. Currently there are no integrated computational-experimental methods specifically designed to search for combinations, maximizing a predefined therapeutic index (TI) defined in terms of appropriate model systems. Here, such a pipeline is presented allowing the search for optimal combinations among an arbitrary number of drugs while also taking experimental variability into account. The TI optimized is the cytotoxicity difference (in vitro) between a target model and an adverse side effect model. Focusing on colorectal carcinoma (CRC), the pipeline provided several combinations that are effective in six different CRC models with limited cytotoxicity in normal cell models. Herein we describe the identification of the combination (Trichostatin A, Afungin, 17-AAG) and present results from subsequent characterisations, including efficacy in primary cultures of tumour cells from CRC patients. We hypothesize that its effect derives from potentiation of the proteotoxic action of 17-AAG by Trichostatin A and Afungin. The discovered drug combinations against CRC are significant findings themselves and also indicate that the proposed strategy has great potential for suggesting drug combination treatments suitable for other cancer types as well as for other complex diseases. |
format | Online Article Text |
id | pubmed-4585751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45857512015-09-29 In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index Kashif, M. Andersson, C. Hassan, S. Karlsson, H. Senkowski, W. Fryknäs, M. Nygren, P. Larsson, R. Gustafsson, M.G. Sci Rep Article In vitro-based search for promising anti-cancer drug combinations may provide important leads to improved cancer therapies. Currently there are no integrated computational-experimental methods specifically designed to search for combinations, maximizing a predefined therapeutic index (TI) defined in terms of appropriate model systems. Here, such a pipeline is presented allowing the search for optimal combinations among an arbitrary number of drugs while also taking experimental variability into account. The TI optimized is the cytotoxicity difference (in vitro) between a target model and an adverse side effect model. Focusing on colorectal carcinoma (CRC), the pipeline provided several combinations that are effective in six different CRC models with limited cytotoxicity in normal cell models. Herein we describe the identification of the combination (Trichostatin A, Afungin, 17-AAG) and present results from subsequent characterisations, including efficacy in primary cultures of tumour cells from CRC patients. We hypothesize that its effect derives from potentiation of the proteotoxic action of 17-AAG by Trichostatin A and Afungin. The discovered drug combinations against CRC are significant findings themselves and also indicate that the proposed strategy has great potential for suggesting drug combination treatments suitable for other cancer types as well as for other complex diseases. Nature Publishing Group 2015-09-22 /pmc/articles/PMC4585751/ /pubmed/26392291 http://dx.doi.org/10.1038/srep14118 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Kashif, M. Andersson, C. Hassan, S. Karlsson, H. Senkowski, W. Fryknäs, M. Nygren, P. Larsson, R. Gustafsson, M.G. In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index |
title | In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index |
title_full | In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index |
title_fullStr | In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index |
title_full_unstemmed | In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index |
title_short | In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index |
title_sort | in vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585751/ https://www.ncbi.nlm.nih.gov/pubmed/26392291 http://dx.doi.org/10.1038/srep14118 |
work_keys_str_mv | AT kashifm invitrodiscoveryofpromisinganticancerdrugcombinationsusingiterativemaximisationofatherapeuticindex AT anderssonc invitrodiscoveryofpromisinganticancerdrugcombinationsusingiterativemaximisationofatherapeuticindex AT hassans invitrodiscoveryofpromisinganticancerdrugcombinationsusingiterativemaximisationofatherapeuticindex AT karlssonh invitrodiscoveryofpromisinganticancerdrugcombinationsusingiterativemaximisationofatherapeuticindex AT senkowskiw invitrodiscoveryofpromisinganticancerdrugcombinationsusingiterativemaximisationofatherapeuticindex AT fryknasm invitrodiscoveryofpromisinganticancerdrugcombinationsusingiterativemaximisationofatherapeuticindex AT nygrenp invitrodiscoveryofpromisinganticancerdrugcombinationsusingiterativemaximisationofatherapeuticindex AT larssonr invitrodiscoveryofpromisinganticancerdrugcombinationsusingiterativemaximisationofatherapeuticindex AT gustafssonmg invitrodiscoveryofpromisinganticancerdrugcombinationsusingiterativemaximisationofatherapeuticindex |